Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+18.3%
5Y CAGR+20.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+18.3%/yr
vs +32.8%/yr prior
5Y CAGR
+20.3%/yr
Consistent
Acceleration
-14.5pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $659.57M | +51.5% |
| 2024 | $435.35M | -3.5% |
| 2023 | $450.99M | +13.1% |
| 2022 | $398.88M | +16.4% |
| 2021 | $342.70M | +30.8% |
| 2020 | $261.94M | +26.6% |
| 2019 | $206.87M | +61.3% |
| 2018 | $128.26M | +38.1% |
| 2017 | $92.88M | +73.2% |
| 2016 | $53.64M | - |